These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 37846681)

  • 1. [Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with
    Weng GY; You WW; Liu HX; Cai Y; DU X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1333-1339. PubMed ID: 37846681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
    Weng G; Huang J; An N; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; He X; Jin H; Liu Q; Du X
    Cancer Med; 2024 Jan; 13(2):e6885. PubMed ID: 38334500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
    Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
    Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of genetic co-mutation on chemotherapeutic outcome in NPM1-mutated and FLT3-ITD wild-type AML patients.
    Wu Q; Zhang Y; Yuan B; Huang Y; Jiang L; Liu F; Yan P; Cheng J; Long Z; Jiang X
    Cancer Med; 2024 Aug; 13(15):e70102. PubMed ID: 39126219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory
    Short NJ; Daver N; Dinardo CD; Kadia T; Nasr LF; Macaron W; Yilmaz M; Borthakur G; Montalban-Bravo G; Garcia-Manero G; Issa GC; Chien KS; Jabbour E; Nasnas C; Huang X; Qiao W; Matthews J; Stojanik CJ; Patel KP; Abramova R; Thankachan J; Konopleva M; Kantarjian H; Ravandi F
    J Clin Oncol; 2024 May; 42(13):1499-1508. PubMed ID: 38277619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
    Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
    Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostication refinement in NPM1-mutated acute myeloid leukemia stratified by FLT3-ITD status with different induction doses of cytarabine.
    Wang B; Hua X; Zhang J; Gu W; Li H
    Cancer Med; 2023 Apr; 12(8):9420-9433. PubMed ID: 36808479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
    Suárez EU; Boluda B; Lavilla E; Tormo M; Botella C; Gil C; Vives S; Rodríguez C; Serrano J; Sayas MJ; Martínez-Sánchez P; Ramos F; Bernal T; Algarra L; Bergua-Burgues JM; Pérez-Simón JA; Herrera P; Barrios M; Noriega-Concepción V; Raposo-Puglia JA; Ayala R; Barragán E; Martínez-Cuadrón D; Amigo ML; López-Lorenzo JL; Lázaro-García A; Guimaraes JE; Colorado M; García-Boyero R; De Rueda-Ciller B; Foncillas-García M; Hong A; Labrador J; Alonso-Dominguez JM; Montesinos P;
    Ann Hematol; 2024 Aug; 103(8):2845-2851. PubMed ID: 38884787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
    Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ
    Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Propensity Score- Matching Study.
    Zhou C; Zheng F; Xu L; Zhang X; Chang Y; Mo X; Sun Y; Huang X; Wang Y
    Transplant Cell Ther; 2023 Jul; 29(7):456.e1-456.e11. PubMed ID: 37028555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
    Petit C; Saillard C; Mohty B; Hicheri Y; Villetard F; Maisano V; Charbonnier A; Rey J; D'Incan E; Rouzaud C; Gelsi-Boyer V; Murati A; Lhoumeau AC; Ittel A; Mozziconacci MJ; Alary AS; Hospital MA; Vey N; Garciaz S
    Eur J Haematol; 2024 Apr; 112(4):530-537. PubMed ID: 38031389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
    Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
    Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and Survival of Venetoclax Based Regimen in the Treatment of Acute Myeloid Leukemia].
    Kong FC; Qi L; Huang WF; Yu M; Zhou YL; Ji DX; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1676-1683. PubMed ID: 38071045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety of gilteritinib-based combination therapy bridging allo-HSCT in relapsed or refractory acute myeloid leukemia patients with positive FLT3-ITD mutation].
    Xu Y; Zhang J; Xue SL; Miao M; Wang Y; Chen SN; Qiu HY; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):357-363. PubMed ID: 38951063
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
    Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
    Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine.
    Zhang LS; Wang J; Xu MZ; Wu TM; Huang SM; Cao HY; Sun AN; Liu SB; Xue SL
    Onco Targets Ther; 2022; 15():159-164. PubMed ID: 35221695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosomal Abnormalities and Prognosis in
    Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas PY; Dombret H; Preudhomme C; Micol JB; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch JH; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
    J Clin Oncol; 2019 Oct; 37(29):2632-2642. PubMed ID: 31430225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax Plus Gilteritinib for
    Daver N; Perl AE; Maly J; Levis M; Ritchie E; Litzow M; McCloskey J; Smith CC; Schiller G; Bradley T; Tiu RV; Naqvi K; Dail M; Brackman D; Siddani S; Wang J; Chyla B; Lee P; Altman JK
    J Clin Oncol; 2022 Dec; 40(35):4048-4059. PubMed ID: 35849791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.